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Background: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) in patients with metastatic
melanoma has been reported to have a 56% overall response rate with 20% complete responders. To increase the
availability of this promising therapy in patients with advanced melanoma, a minimally invasive approach to
procure tumor for TIL generation is warranted.
Methods: A feasibility study was performed to determine the safety and efficacy of laparoscopic liver resection to
generate TIL for ACT. Retrospective review of a prospectively maintained database identified 22 patients with
advanced melanoma and visceral metastasis (AJCC Stage M1c) who underwent laparoscopic liver resection
between 1 October 2005 and 31 July 2011. The indication for resection in all patients was to receive postoperative
ACT with TIL.
Results: Twenty patients (91%) underwent resection utilizing a closed laparoscopic technique, one required
hand-assistance and another required conversion to open resection. Median intraoperative blood loss was 100 mL
with most cases performed without a Pringle maneuver. Median hospital stay was 3 days. Three (14%) patients
experienced a complication from resection with no mortality. TIL were generated from 18 of 22 (82%) patients.
Twelve of 15 (80%) TIL tested were found to have in vitro tumor reactivity. Eleven patients (50%) received the
intended ACT. Two patients were rendered no evidence of disease after surgical resection, with one undergoing
delayed ACT with generated TIL after relapse. Objective tumor response was seen in 5 of 11 patients (45%) who
received TIL, with one patient experiencing an ongoing complete response (32+ months).
Conclusions: Laparoscopic liver resection can be performed with minimal morbidity and serve as an effective
means to procure tumor to generate therapeutic TIL for ACT to patients with metastatic melanoma.
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In 2010, the estimated incidence of melanoma was 68,130
with approximately 8,700 deaths [1]. The annual incidence
of melanoma continues to increase [1,2]. Metastatic mel-
anoma has a poor prognosis with a median survival of 6
to 8 months and a 5-year survival of approximately 6%
[3,4]. Liver metastases are diagnosed in 10 to 20% of
patients with metastatic melanoma and are associated* Correspondence: udai_kammula@nih.gov
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distribution, and reproduction in any mediumwith a poor prognosis and decreased mean survival of
4.4 months [5].
The Food and Drug Administration (FDA) has
approved four systemic therapies for the treatment of
patients with metastatic melanoma. Systemic high-dose
IL-2 has an objective response rate of approximately
15% and a durable long-term complete response rate
of 4 to 5% [6]. Dacarbazine has an objective response
rate of 12% with 2 to 3% complete responses that are
rarely durable [7]. Most recently, two additional agents
have been approved [6-11]. Ipilimumab, an antibody
against the inhibitory lymphocyte receptor CTLA-4,d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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improvement in median survival of 3.6 months [8]
compared to a vaccine treatment arm. Vemurafinib, a
BRAF kinase inhibitor, was shown in a randomized
controlled trial to have a 48% overall response rate;
however, the response duration is short lived [12,13].
Thus, current approved treatment options for patients
with metastatic melanoma, while promising, are asso-
ciated with variable response rates and rare durable
complete responders [6-11].
The National Cancer Institute, Surgery Branch, has
focused on adoptive cell therapy (ACT) of autologous
tumor-infiltrating lymphocytes (TIL) as a promising
treatment for metastatic melanoma which has been
shown in phase II trials to result in durable complete
responses [14-19]. To generate a TIL infusion product,
a tumor is resected to isolate TIL, which then undergo
ex vivo expansion. The cells are then infused back into
a lympho-depleted patient concomitantly with high
dose IL-2. Recent data with TIL ACT have shown a
clinical response rate by Response Evaluation Criteria
in Solid Tumors (RECIST) in 52 of 93 (56%) patients
with metastatic melanoma and a durable complete re-
sponse rate of 20% [14].
TIL ACT has thus emerged as an additional effective
therapy for patients with advanced metastatic melan-
oma. Based upon growing experience with ACT, more
extensive operations to procure tumor tissue to gener-
ate TIL have been undertaken in these patients. Two
recent studies evaluated the results of thoracic and
hepatic metastasectomy for generation of TIL for ACT
[20,21]. Both studies showed prolonged survival in
patients who underwent metastasectomy and who were
treated with TIL compared to those who did not re-
ceive TIL. A significant drawback from these studies is
that aggressive surgical metastasectomy performed
solely for the purpose of procuring TIL carries a risk
of known morbidity and mortality associated with
major visceral resection. Surgical complications might
delay, or even preclude, eventual adoptive transfer of
TIL. In this study, we describe our laparoscopic ap-
proach for hepatic tumor procurement as a minimally
invasive procedure for the procurement of TIL from
liver metastases.
The objective of this study was to determine the feasi-
bility of laparoscopic liver resection as a means of
obtaining hepatic TIL for the systemic treatment of
patients with advanced metastatic melanoma in the Sur-
gery Branch, National Cancer Institute, National Insti-
tutes of Health. Specifically, we sought to determine the
safety of laparoscopic liver resection, examine overall pa-
tient outcome after TIL procurement and ACT, and de-
termine if laparoscopic liver resection is an effective
means in which of procuring TIL.Methods
Patients
A retrospective review of a prospectively maintained
database identified 22 patients who underwent attempted
laparoscopic liver resection with a diagnosis of melan-
oma at the National Cancer Institute, Surgery Branch,
from 1 October 2005 to 31 July 2011. All patients signed
an institutional review board approved consent form
for tissue procurement and participation in subsequent
immunotherapy protocols if the patient required fur-
ther systemic therapy. Inclusion criteria included patho-
logically confirmed melanoma, 18 years of age or older,
negative serology for HIV, Hepatitis B and C, good per-
formance status (Eastern Cooperative Oncology Group
≤2) and life expectancy greater than 3 months.
Surgical intervention and continuing care
Complete staging was performed with history and phys-
ical examination, laboratory assessment, computed tomo-
graphic examination of the chest, abdomen and pelvis,
and magnetic resonance imaging of the brain for all
patients. Additional studies were performed based on
individual patient assessments. Patients did not necessar-
ily have pathologic confirmation of melanoma in the liver
before the operation. Postoperative pathology confirmed
melanoma in all patients. Suitability of liver resection was
based on the patient’s ability to tolerate an operation, pace
of disease progression and likelihood of participation in
subsequent ACT protocols. The ability to render a patient
with no evidence of disease was not a criterion for surgi-
cal resection. The decision to proceed with liver resection
was made on a case-by-case basis after presentation at
the Surgery Branch Immunotherapy conference. The
decision to resect lesions using minimally invasive tech-
niques was based on the attending hepatobiliary surgeon’s
recommendations (USK).
Laparoscopic surgical technique
Laparoscopic resection was performed on each patient
in lithotomy or supine position. Carbon dioxide pneu-
moperitoneum was achieved with intra-abdominal pres-
sure maintained between 12 and 15 mmHg. A 12-mm
periumbilical port was placed using the Hassan tech-
nique for a 30 degree laparoscope (Figure 1). Additional
port sites were placed in triangulation to allow optimal
visualization and mobilization of the liver. In most cases
we used one additional 12-mm and two 5-mm ports.
The initial step was to perform visual inspection of the
liver followed by laparoscopic ultrasound to determine
the location and extent of intraparenchymal lesions, lo-
cation of inflow pedicles and draining veins, as well as to
note any biliary tree involvement.
The appropriate resection line was marked on Glis-
son’s capsule utilizing argon electrocautery. A Pringle
Figure 1 Position of ports for laparoscopic liver resection. The
30 degree laparoscope was inserted via a 12-mm periumbilical
incision (1). A subxiphoid 5-mm port was used for liver retraction (2).
Two working ports, one 5-mm and one 12-mm port, were placed
along the right mid-abdomen (3, 4).
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used, an umbilical tape was passed laparoscopically
around the porta hepatis and intermittent occlusion was
applied as necessary. Parenchymal transection was per-
formed with ultrasonic coagulating shears (HarmonicW
Device, Ethicon Endo-Surgery, Cincinnati, OH, USA)
and an endovascular stapler (Endo GIATM, Covidien,
Norwalk, CT, USA) when a vascular pedicle was encoun-
tered. Hemostatis of the raw liver surface was achieved
with argon electrocautery and topical hemostatic agents
(FlosealW, Baxter, Deerfield, IL, USA and AviteneTM,
Bard Davol Inc., Warwick, RI, USA). The specimen was
removed in an impermeable bag (Endo CatchTM, Ethicon
Endo-Surgery, Cincinnati, OH, USA).
A low CVP (Central Venous Pressure) of 4 to 6
cmH2O to minimize intraoperative blood loss was main-
tained in each case utilizing fluid limitation, anesthetic
techniques and patient positioning. The majority of sur-
gical procedures were performed by a single surgeon
(USK) with a standardized operative approach.
Tumor-infiltrating lymphocyte production
and administration
All tumors were processed in the Cell Production Facil-
ity within the Surgery Branch at the National Cancer
Institute for isolation of TIL using techniques described
previously [22]. Before July 2007, the activity and specifi-
city of generated TIL were evaluated by measuring IFNγ
secretion of TIL in response to a panel of tumor targets,
allogeneic melanoma cell lines, fresh autologous tumor
cells and peptide-pulsed T2 cells. After July 2007,cultures which successfully yielded TIL were adminis-
tered without in vitro reactivity analysis due to concerns
that these assays lacked sufficient sensitivity and specifi-
city to accurately reflect in vivo efficacy [23].
TIL which met criteria for infusion underwent rapid
expansion with OKT3 (anti-CD-3) antibody (Ortho Biotech,
Bridgewater, NJ, USA), recombinant IL-2 (Chiron Corp.,
Emeryville, CA, USA), and irradiated peripheral blood
mononuclear cells (PBMCs). Patients received a nonmyeloa-
blative (NMA) chemotherapy regimen with cyclophospha-
mide (60 mg/kg) for 2 days and fludarabine (25 mg/m2)
for 5 days. One patient additionally received 2 Gy total
body irradiation with autologous CD34+ cells. Approxi-
mately 5× 1010 TIL cells were administered to the autolo-
gous host by a 30-minute intravenous infusion after the
patient completed the NMA regimen. TIL infusion was fol-
lowed by 720,000 IU/kg of intravenous IL-2 every 8 hours
up to 15 doses or until dose limiting toxicity was seen.
Evaluation of response
The patients were assessed for tumor response to therapy
based on World Health Organization (WHO) criteria or
Response Evaluation Criteria in Solid Tumors (RECIST)
every month for 6 months, then every 3 months for a
year and every 6 months thereafter with radiographic
imaging. Complete responders had no radiographic evi-
dence of residual tumor after therapy. Partial responders
exhibited a 30% or greater decrease in the sum of the
longest diameters of their target lesions. Patients were
deemed as having progressive disease if they exhibited a
20% or greater increase in the sum of the longest dia-
meters of their target lesions or had new lesions.
Statistical analysis
The overall survival (OS) was calculated from the date
of ACT until the date of last encounter or death. The




From 1 October 2005 until 31 July 2011, 592 patients
with advanced metastatic melanoma underwent surgical
resection for TIL procurement. Of these, 22 patients
with visceral metastasis (AJCC Stage M1c disease) were
taken to surgery for attempted laparoscopic liver resec-
tion (Table 1). Eighteen (82%) patients had received
prior systemic treatment before presenting to the Na-
tional Institutes of Health. Of those, 11 (50%) were trea-
ted with high dose IL-2 and 10 (45%) with IFN alpha 2b.
In all, 45% of patients received one previous treatment
regimen, 14% received two different regimens and 23%
received three or more regimens including chemother-
apy, biochemotherapy, vaccines or investigational trials
Table 1 Clinical characteristics of 22 patients with
metastatic melanoma who underwent laparoscopic liver
resection for tumor-infiltrating lymphocyte harvest
Variable n %
Number of patients 22







IFN alpha 2b 10 45




Anti-CTLA-4 antibody 2 9
Tyrosine kinase inhibitor 1 4.5





*Biochemotherapy = chemotherapy combined with IL-2 or IFN alpha 2b. TIL,
tumor-infiltrating lymphocyte; NED, no evidence of disease.
Table 2 Operative characteristics of 22 patients with
metastatic melanoma who underwent laparoscopic liver
resection for tumor-infiltrating lymphocyte harvest
Variable n %
Surgical approach
Laparoscopic, completely closed 20 90
Hand-assisted laparoscopic 1 4.5
Lap converted to open 1 4.5
No. of metastases resected 45
1 14 64
2 3 14
≥ 3 5 23
Segment of liver resected
Combined segment 2 and 3 2 9
Segment 3 8 36
Segment 5 2 9
Segment 6 8 36
Segment 7 1 4.5
Segment 8 1 4.5
Size (cm) of tumor resected (mean/median (range)) 3.4/3 (0.3-8)
Operative specifics (mean/median (range))
Intraoperative blood loss (mL) 256/100
(50–1400)
Operative time (minutes) 194/193
(90–305)
Use of pringle 3 14
Parenchymal transection with ultrasonic device 21 95
Parenchymal transection with endovascular stapler 15 68
Duration of hospitalization (days) (mean/median (range)) 4/3
(1–10)
Postoperative complication 3 14
Bile leak 1 4.5
Rapid atrial fibrillation 1 4.5
Colitis 1 4.5
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received ACT with gene modified peripheral blood lym-
phocytes. The indication for metastasectomy in all
patients was procurement of TIL. Two (10%) patients
were rendered no evidence of disease (NED) after sur-
gery. One of these patients experienced disease recur-
rence following liver resection and received therapy with
cryopreserved TIL 1 year later. Of the remaining 20
patients, 19 (95%) had extrahepatic disease. One patient
had extensive liver involvement and underwent segmen-
tal resection of segment 3 to procure tumor for TIL.
Operative findings and outcomes
All cases commenced with a closed laparoscopic tech-
nique. Of the 22 patients who underwent surgical resec-
tion, 20 (91%) had resection using a completely closed
laparoscopic technique (Table 2). One patient required
hand-assistance due to the location and inadequate
visualization of the tumor in the superior part of seg-
ment 7. Another required conversion to open resection
for bleeding that was uncontrolled with a Pringle man-
euver. Fifty-four tumors were harvested from 22
patients. Most patients (64%) had a single liver metasta-
sis harvested for TIL therapy, while eight (37%) patientshad more than two tumors resected (up to 10). The ma-
jority of resections were either formal segmental resec-
tions (41%) or non-anatomical wedge resections (59%).
There were no laparoscopic liver lobectomies performed
in this series. The most common sites of procurement
were from segment 3 (36%) and 6 (36%). The average
size of tumor resected was 3.4 cm, with a range in size
of 0.3 to 8 cm. Most procedures were performed without
a Pringle (86%) and with the use of ultrasonic coagulat-
ing shears (95%) to divide the hepatic parenchyma. In
addition, an endovascular stapler was used in 68% of
procedures. Median estimated blood loss was 100 mL
with a median operative time of 193 minutes.
The median duration of inpatient hospitalization was
3 days, ranging from 1 to 10 days. There was no mortality
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three patients experiencing a perioperative complication
(Table 2). One patient developed a postoperative bile leak
which was managed conservatively and resolved in
20 days. This patient required a longer hospitalization of
10 days and experienced a 1-month time delay in recei-
ving TIL. One patient developed new-onset atrial fibrilla-
tion requiring electrocardioversion in the immediate
postoperative period. There was no delay for this patient
to receive TIL. Finally, one patient developed ascending
colitis on postoperative day 5 of uncertain etiology. This
patient was managed conservatively with antibiotic ther-
apy and discharged home on postoperative day 7. This
complication did not result in a delay to TIL therapy.
Tumor-infiltrating lymphocyte characteristics and clinical
outcomes
Fifty-five tumors from 22 patients were analyzed for TIL
testing (Table 3). Because multiple tumors can be used
to generate a single therapeutic TIL treatment, all
tumors harvested for a single patient were considered asTable 3 Results of tumor-infiltrating lymphocyte growth,
activity and therapy
Variable n %







Not tested 3 17
Treatment after metastasectomy
TIL 11 50
No TIL 11 50
Reasons not to receive TIL therapy
NED 1 5
TIL did not grow 4 18
TIL was not reactive 2 9
Rapid disease progression 3 16
Enrollment on another protocol 1 5
Death 0 0
Objective response to TIL
Complete response 1 9
Partial response 4 36
No response (disease progression) 6 55
Median time (days) to receive TIL 37
Average time (days) to receive TIL (range) 84 (35–416)
TIL, tumor-infiltrating lymphocyte; NED, no evidence of disease.a single TIL specimen. TIL cultures from 18 of the 22
(82%) patients demonstrated adequate growth (Figure 2).
Of these growth-positive cultures, 15 were tested for
reactivity against HLA (Human Leukocyte Antigen)
matched tumor lines according to The TIL Laboratory
criteria [22]. Three of the growth-positive TIL were not
tested for reactivity because the respective patients were
excluded from therapy due to rapid disease progression.
Of the 15 TIL tested for reactivity, 12 (80%) were con-
sidered sufficiently reactive for administration as previ-
ously described [22]. In all, of the 22 patients who
underwent liver resection, 11 (50%) received intended
ACT therapy. Reasons to not receive TIL included rapid
disease progression (3/22), TIL did not grow (4/22), TIL
cultures were not reactive (2/16), resection to NED status
(1/22), and enrollment onto another clinical trial (1/22).
All patients were evaluated postoperatively and were
typically ready to receive systemic therapy within 1 to
2 weeks after surgical resection. One exception was in
the patient who experienced a postoperative biloma.
This patient was ready to receive systemic therapy
4 weeks after surgical resection.
The median follow-up time was 9.5 months for the 11
patients receiving adoptive cell therapy with TIL. Over-
all, there were five responders (45% response rate, 23%
based on intention to treat). One patient (4.5%) had a
complete response according to RECIST criteria (Fig-
ure 3). This has been an ongoing response for more than
32 months since therapy. Four (36%) patients had a par-
tial response. Six (27%) patients did not respond to cell
transfer. The median overall survival of patients receiv-
ing TIL therapy was 21.7 months.
Discussion
Patients with metastatic melanoma have a median sur-
vival of 6 to 8 months and a 5-year survival of 6% [3,4].
FDA-approved treatments for metastatic melanoma
including IL-2, chemotherapy, ipilimumab, and vemurafe-
nib have variable response rates and rarely result in dur-
able complete responses. With limited therapies available,
efforts to develop novel regimens are critical.
The Surgery Branch at The National Cancer Institute,
National Institutes of Health, has studied ACT utilizing
autologous TIL as a therapy for metastatic melanoma.
Recent analysis of 93 patients has shown a 56% clinical
response rate with adoptive transfer of TIL [12]. Based
upon these encouraging results, efforts to improve the
surgical strategy for tumor procurement is an ongoing
focus of the Surgery Branch. In this study, we sought to
examine the role of laparoscopic liver resection to obtain
tumor tissue to generate TIL for ACT in patients with
advanced metastatic melanoma.
Metastases to the liver occur in 40 to 80% of patients
with ocular melanoma and 10 to 20% of patients with
Figure 2 Flow diagram of patients undergoing laparoscopic liver metastasectomy for tumor-infiltrating lymphocyte therapy. Fifty
percent of patients received the intended tumor-infiltrating lymphocyte (TIL) therapy. *Of the three patients without reactive TIL, one patient was
rendered no evidence of disease and did not require treatment, the remaining two patients received other therapies.
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portant site for tumor procurement [5,10,24]. While it is
optimal for a patient to undergo a low-morbidity proced-
ure to generate TIL, in some patients liver metastases rep-
resent the only viable option to obtain sufficient tumor. In
other surgical specialties, minimally invasive approaches
have been found to be cost-effective and equivalent to
open procedures in outcome [25-27]. In addition, these
procedures are associated with decreased morbidity,
decreased hospital stay and expedient postoperative rec-
overy. Similarly, efforts examining laparoscopic versus
open liver resection of benign and malignant tumors
have demonstrated efficacy and safety in utilizing a lap-
aroscopic approach [28-30]. Laparoscopic liver resection
is associated with decreased hospitalization and costs
[28,29,31,32], with the average postoperative hospital stay
reported as 1.7 to 3.2 days [29,33-35].
Here, we retrospectively examined 22 patients who
underwent planned laparoscopic liver resection to
generate TIL for ACT. Successful closed laparoscopic
resection was performed in 91% of patients. To be
considered for resection, a patient was required to be
medically stable without evidence of underlying liver
disease or life threatening co-morbidities, have a goodperformance status, and possess favorable tumor biology.
These important considerations were to ensure a patient
could tolerate intraoperative hemodynamic changes asso-
ciated with liver resection, as well as postoperative stress
inherent to any major visceral resection. In this series,
we report a morbidity of 14% with no mortality. Overall
morbidity has been cited in the literature to be between
6 and 22% after laparoscopic liver resection [29,30,36-38]
which is comparable with our findings. Additionally, only
one case required conversion from laparoscopic to open
resection secondary to bleeding, further supporting lap-
aroscopic resection as a safe and feasible option to gen-
erate TIL.
A significant concern in laparoscopic liver resection
is the ability to limit intraoperative blood loss. Paren-
chymal transection utilizing ultrasonic coagulating shears
and an endovascular stapler for vascular pedicle division
has been well established. In our experience, we found
hemostasis was best accomplished utilizing the HarmonicW
Device (Ethicon Endo-Surgery, Cincinnati, OH, USA) in
conjunction with an endovascular stapler (Endo GIA™,
Covidien, Norwalk, CT, USA) when a significant vascular
pedicle was encountered. We did not routinely require a
Pringle maneuver. With these techniques, the median
Figure 3 Overall survival of patients (n = 11) undergoing laparoscopic liver resection who received postoperative tumor-infiltrating
lymphocytes. Median survival was 21.7 months.
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that documented by others [33-35,39].
Recently, in a report of 300 laparoscopic liver resec-
tions performed over 10 years, Cannon and colleagues
describe a trend towards increasingly complex resections
as the authors gained experience [39]. Similarly, we ini-
tially favored anterior and peripherally located tumors
for ease of resection. We avoided laparoscopic resection
of tumors with a central location or close proximity to
major portal or hepatic vascular structures and instead
opted to resect these tumors with a traditional open ap-
proach. With experience, we have transitioned to resect-
ing these more challenging tumors laparoscopically.
Currently, we are building on our experience to perform
formal laparoscopic lobectomy when this represents the
sole option for generation of TIL in a given patient.
Overall, patients were typically back to daily activities
and off all narcotics within 1 to 2 weeks. Only one pa-
tient experienced a delay to TIL therapy due to a com-
plication associated with resection. This is an important
finding given the intensity of the NMA preparative regi-
men necessary before TIL cell infusion. Thus, we conclude
from this pilot experience that patients with metastases to
the liver can undergo a minimally invasive procedure and
receive ACT in a timely manner.
Finally, we examined the efficacy of TIL generated
from laparoscopic liver resection and its translation intopatient therapy and outcome. Of the patients who
underwent resection, 82% had growth-positive TIL, with
12 (66%) patients demonstrating adequate reactivity to
undergo expansion for ACT. This is comparable to pre-
viously published reports from the Surgery Branch
[20,21]. Of note, many patients in these previous reports
were subjected to major open surgical resections, such
as thoracotomy, sternotomy or open hepatic resection.
Of the 22 patients who underwent laparoscopic liver re-
section, 11 received the intended TIL therapy (50%).
Overall, there was one (9%) documented complete re-
sponse (duration 32+ months), four (36%) partial
responders and five (45%) non-responders with an over-
all response rate of 45% or 23% based on preoperative
intention-to-treat analysis. These response data are
comparable to our previously published results of 29%
and 40% response rates (8% and 25% intention-to-treat)
after thoracic metastasectomy or open liver resection,
respectively [14,20,40]. The median overall survival was
21.7 months. These findings emphasize that patient
selection is important for successful ACT and also suggest
that, as we improve upon the methods for TIL generation
to treat more patients, we may further improve overall
response rates.
Potential limitations of this study include the retrospect-
ive nature of data analysis and patient selection bias.
Patients who are candidates for TIL therapy may represent
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favorable tumor biology, allowing them to undergo tumor
procurement and wait the necessary month for TIL gener-
ation. Further selection bias includes the selection of
patients to undergo laparoscopic versus open liver resec-
tion. Despite these caveats, our current description is a
valuable additional therapeutic option for patients with
advanced metastatic melanoma.
Conclusions
In conclusion, we found laparoscopic liver resection in
well selected patients to be feasible with minimal mor-
bidity and no mortality. This represents an important
and effective option for patients with hepatic metastases
who are candidates for ACT.
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